X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CADILA HEALTHCARE - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CADILA HEALTHCARE AUROBINDO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 18.0 35.2 51.1% View Chart
P/BV x 5.8 9.1 64.5% View Chart
Dividend Yield % 0.4 0.7 52.5%  

Financials

 AUROBINDO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
CADILA HEALTHCARE
Mar-16
AUROBINDO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,541454 339.0%   
Low Rs582305 191.1%   
Sales per share (Unadj.) Rs237.596.1 247.1%  
Earnings per share (Unadj.) Rs33.914.9 227.7%  
Cash flow per share (Unadj.) Rs40.617.8 227.7%  
Dividends per share (Unadj.) Rs2.503.20 78.1%  
Dividend yield (eoy) %0.20.8 27.9%  
Book value per share (Unadj.) Rs120.652.3 230.7%  
Shares outstanding (eoy) m585.171,023.74 57.2%   
Bonus/Rights/Conversions PREFFV5:1-  
Price / Sales ratio x4.53.9 113.2%   
Avg P/E ratio x31.325.5 122.8%  
P/CF ratio (eoy) x26.221.3 122.9%  
Price / Book Value ratio x8.87.3 121.2%  
Dividend payout %7.421.5 34.3%   
Avg Mkt Cap Rs m621,041388,458 159.9%   
No. of employees `00013.315.4 86.1%   
Total wages/salary Rs m15,50813,317 116.5%   
Avg. sales/employee Rs Th10,457.66,371.1 164.1%   
Avg. wages/employee Rs Th1,167.1862.4 135.3%   
Avg. net profit/employee Rs Th1,491.6986.1 151.3%   
INCOME DATA
Net Sales Rs m138,96198,376 141.3%  
Other income Rs m1,663941 176.7%   
Total revenues Rs m140,62499,317 141.6%   
Gross profit Rs m32,05623,829 134.5%  
Depreciation Rs m3,9263,022 129.9%   
Interest Rs m2,568486 528.3%   
Profit before tax Rs m27,22521,262 128.0%   
Minority Interest Rs m39-300 -13.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m7,4445,716 130.2%   
Profit after tax Rs m19,82015,226 130.2%  
Gross profit margin %23.124.2 95.2%  
Effective tax rate %27.326.9 101.7%   
Net profit margin %14.315.5 92.2%  
BALANCE SHEET DATA
Current assets Rs m100,01544,376 225.4%   
Current liabilities Rs m74,75934,071 219.4%   
Net working cap to sales %18.210.5 173.5%  
Current ratio x1.31.3 102.7%  
Inventory Days Days10754 199.4%  
Debtors Days Days11062 175.8%  
Net fixed assets Rs m52,35047,896 109.3%   
Share capital Rs m5851,024 57.1%   
"Free" reserves Rs m67,70748,746 138.9%   
Net worth Rs m70,56753,519 131.9%   
Long term debt Rs m8,4728,964 94.5%   
Total assets Rs m156,994100,163 156.7%  
Interest coverage x11.644.7 25.9%   
Debt to equity ratio x0.10.2 71.7%  
Sales to assets ratio x0.91.0 90.1%   
Return on assets %14.315.7 90.9%  
Return on equity %28.128.4 98.7%  
Return on capital %37.734.3 110.1%  
Exports to sales %51.045.3 112.7%   
Imports to sales %18.85.9 317.6%   
Exports (fob) Rs m70,92744,537 159.3%   
Imports (cif) Rs m26,1935,838 448.7%   
Fx inflow Rs m71,01544,881 158.2%   
Fx outflow Rs m28,7999,069 317.6%   
Net fx Rs m42,21635,812 117.9%   
CASH FLOW
From Operations Rs m17,59619,938 88.3%  
From Investments Rs m-13,801-9,039 152.7%  
From Financial Activity Rs m-198-9,527 2.1%  
Net Cashflow Rs m3,5971,372 262.2%  

Share Holding

Indian Promoters % 54.1 74.8 72.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 8.3 95.8%  
FIIs % 27.7 5.9 469.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 11.0 92.7%  
Shareholders   69,601 44,069 157.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS